129 related articles for article (PubMed ID: 21512394)
1. Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301).
Komatsu Y; Takahashi Y; Kimura Y; Oda H; Tajima Y; Tamura S; Sakurai J; Wakasugi T; Tatebe S; Takahashi M; Sakata Y; Kitajima M; Sakamoto J; Saji S
Anticancer Drugs; 2011 Jul; 22(6):576-83. PubMed ID: 21512394
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).
Narahara H; Iishi H; Imamura H; Tsuburaya A; Chin K; Imamoto H; Esaki T; Furukawa H; Hamada C; Sakata Y
Gastric Cancer; 2011 Mar; 14(1):72-80. PubMed ID: 21340666
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
Nakashima K; Hironaka S; Boku N; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Kojima T; Machida N
Jpn J Clin Oncol; 2008 Dec; 38(12):810-5. PubMed ID: 18988666
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).
Uedo N; Narahara H; Ishihara R; Takiuchi H; Goto M; Fujitani K; Hirao M; Tsujinaka T; Imano M; Furukawa H; Tsukuma H; Taguchi T
Oncology; 2007; 73(1-2):65-71. PubMed ID: 18334851
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy.
Takahashi Y; Sakamoto J; Takeuchi T; Mai M; Kubota T; Kitajima M; Tanigawara Y; Komatsu Y; Toge T; Saji S
Jpn J Clin Oncol; 2004 Jun; 34(6):342-5. PubMed ID: 15333687
[TBL] [Abstract][Full Text] [Related]
7. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.
Han B; Jung JY; Kim HS; Cho JW; Kim KC; Lim H; Kang HS; Ha HI; Kim MJ; Kim JH; Choi DR; Jang G; Kim JH; Song H; Zang DY
Cancer Chemother Pharmacol; 2016 Nov; 78(5):949-958. PubMed ID: 27628195
[TBL] [Abstract][Full Text] [Related]
8. [A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)].
Takahashi Y; Takeuchi T; Sakamoto J; Mai M; Kitajima M; Kubota T; Toge T; Saji S
Gan To Kagaku Ryoho; 2004 Nov; 31(12):1969-72. PubMed ID: 15570922
[TBL] [Abstract][Full Text] [Related]
9. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
[TBL] [Abstract][Full Text] [Related]
10. Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.
Takahari D; Shimada Y; Takeshita S; Nishitani H; Takashima A; Okita N; Hirashima Y; Kato K; Hamaguchi T; Yamada Y; Shirao K
Gastric Cancer; 2010 Aug; 13(3):186-90. PubMed ID: 20820988
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
Yamada Y; Yasui H; Goto A; Arai T; Ura T; Hamaguchi T; Muro K; Shimada Y; Shirao K
Int J Clin Oncol; 2003 Dec; 8(6):374-80. PubMed ID: 14663640
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
13. [Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].
Akasaka O; Iwase S; Miwa H; Ando T; Morita S; Koh R; Kasama M; Matsueda R; Anan H
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1833-7. PubMed ID: 19920384
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer.
Katsube T; Ogawa K; Ichikawa W; Fujii M; Tokunaga A; Takagi Y; Kochi M; Hayashi K; Kubota T; Aiba K; Arai K; Terashima M; Kitajima M
Anticancer Drugs; 2007 Jun; 18(5):605-10. PubMed ID: 17414630
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
[TBL] [Abstract][Full Text] [Related]
16. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
17. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
Komatsu Y; Yuki S; Fuse N; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Sakata Y; Asaka M
Adv Ther; 2010 Jul; 27(7):483-92. PubMed ID: 20559897
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).
Takiuchi H; Narahara H; Tsujinaka T; Gotoh M; Kawabe S; Katsu K; Iishi H; Tatsuta M; Fujitani K; Furukawa H; Taguchi T;
Jpn J Clin Oncol; 2005 Sep; 35(9):520-5. PubMed ID: 16141295
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
Baba E; Esaki T; Ariyama H; Mitsugi K; Morikita T; Fujishima H; Kusaba H; Nakano S; Akashi K
Cancer Chemother Pharmacol; 2011 Sep; 68(3):611-7. PubMed ID: 21116623
[TBL] [Abstract][Full Text] [Related]
20. [S-1 for gastric cancer-S-1 monotherapy and its progress].
Shitara K; Sakata Y; Kudou T; Munakata M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():43-51. PubMed ID: 16897971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
